By Alexander Diegel
Layne Oliff was an active runner who successfully completed 10-mile trail runs up until his 60th birthday — before he was diagnosed with amyotrophic lateral sclerosis (ALS) in November of 2020. Layne soon pivoted that same drive and commitment to another journey, as an active advocate in the ALS community.Continue reading
TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as Executive Director for its two newest public-private partnerships: the Critical Path for Lysosomal Diseases (CPLD) and the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortia . Klein brings a wealth of experience, having previously served as Executive Director of C-Path’s Transplant Therapeutics Consortium (TTC), where she orchestrated successful composite biomarker qualification submissions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency.Continue reading
Allin and Breton join C-Path Board of Directors to support strategic visionContinue reading
TUCSON, Ariz., March 28, 2024 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.Continue reading
Appointments of Seasoned Researchers Reinforce C-Path’s Leadership in Accelerating Innovative Therapy DevelopmentContinue reading
Collaboration will generate evidence to contribute to FDA qualification of a patient-centered, accelerometer-based clinical outcome assessment in CHFContinue reading
Ollivier to steer global strategic initiatives, reinforcing C-Path’s commitment to accelerating medical innovation and regulatory science.Continue reading